Document is current
Any future updates will be listed below
-
Authors
Camoin, Marion
Velho, Gilberto
Saulnier, Pierre-Jean
Potier, Louis
Abouleka, Yawa
Carpentier, Charlyne
Dubois, Severine
Larroumet, Alice
Rigalleau, Vincent
Gand, Elise
Bourron, Olivier
Bordier, Lyse
Scheen, André
Hadjadj, Samy
Roussel, Ronan
Marre, Michel
Mohammedi, Kamel
- License Information
-
More Information
Article History
Received: 3 February 2022
Accepted: 28 February 2022
First Online: 9 May 2022
Declarations
:
: The Ethics Committee of Angers University Hospital (Angers, France) approved the SURGENE, GENEDIAB and GENESIS protocols, and all participants provided written informed consent.
: Not applicable.
: L.P. reports personal fees and non-financial support from Sanofi, Novo Nordisk, Eli Lilly and MSD. VR had grants from the Servier Diabetes institute, Roche, and Merck Lipha Santé. O.B. reports personal fees and non-financial support from MSD and Sanofi. L.B. reports personal fees and non-financial support from Astra Zeneca, Bayer, BD, BMS, Boerhinger Ingelheim, MSD, Novartis, Lilly, Novo Nordisk, Roche, and Sanofi. AS has received lecturer/advisor fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp and Dohme, Novartis, NovoNordisk, Sanofi and Servier. SH reports personal fees and non-financial support from Astra Zeneca, grants and personal fees from Bayer, personal fees from Boehringer Ingelheim, grants from Dinno Santé, personal fees from Eli Lilly, non-financial support from LVL, personal fees and non-financial support from MSD, personal fees from Novartis, grants from Pierre Fabre Santé, personal fees and non-financial support from Sanofi, personal fees and non-financial support from Servier, personal fees from Valbiotis. RR reports research grants from Sanofi, Novo Nordisk, and Diabnext, consulting and speakers’ bureau fees (compensation donated to the nonprofit Foundation APHP for Research) from Sanofi, Novo Nordisk, Eli Lilly, Boehringer-Ingelheim, Mundipharma, Janssen, AstraZeneca, MSD, Medtronic, and Abbott. MM is a consultant for Novo-Nordisk Algerian subsidiary, and has received personal fees from Novo-Nordisk, Merck-Sharp and Dohme, and Eli Lilly. KM reports personal fees or non-financial support from Novo Nordisk, Sanofi, Astra-Zeneca, Eli Lilly, Abbott, Boehringer-Ingelheim and LifeScan. Authors declare no other potential conflict of interest relevant to this article.
